JUN and melanoma: In addition to the observation that all melanomas of mice from the group treated with the combination had reduced phospho-ERK1/2 levels, there was a significant increase in JUN protein levels after the combination treatment with trametinib and DSF in all three BRAF WT PDX models even after the single application of the drugs.